Main Menu

Satsuma Pharmaceuticals, Inc.

Rigrodsky Law, P.A. is investigating Satsuma Pharmaceuticals, Inc. (“Satsuma”) regarding possible breaches of fiduciary duties and other violations of law related to Satsuma’s agreement to be acquired by Shin Nippon Biomedical Laboratories, Ltd. Under the terms of the agreement, Satsuma shareholders will receive $0.91 per share in cash.

Join This Action

Alternatively, you may upload your transactions using the upload button below or email them to

Draw your signature below using your mouse* [Clear]

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

Date of signing: 04/25/2024

* Indicates a required field.

Back to Page